EMA · European Union
nonacog beta pegol — EMA regulatory status
nonacog beta pegol (REFIXIA) regulatory status in the European Union is tracked from public EMA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: EMA approved.
Status snapshot
- Status
- EMA approved
- Brand
- REFIXIA
- Mechanism
- Coagulation factor IX exogenous protein
- Target
- Coagulation factor IX
- Structured fields
- 6
Pharmacology context used for competitive intelligence: Coagulation factor IX exogenous protein. Target: Coagulation factor IX. This page is a status aggregation for professional reference — not prescribing advice.
Regional decision snapshot — EMA: approved.
Linked evidence on this spoke: 1 published clinical program and 0 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| EMA | European Union | approved | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| nonacog beta pegol | Phase 3 | Novo Nordisk A/S | NCT02141074 |
Related hubs
FAQ
What is the EMA approval status of nonacog beta pegol?
nonacog beta pegol currently shows EMA approved in our European Union regulatory index. Confirm on the official EMA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get nonacog beta pegol regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to nonacog beta pegol?
This spoke lists 1 published program associated with nonacog beta pegol in our pipeline index.